Filed Pursuant to Rule 424(b)(3)
Registration No. 333-265337
PROSPECTUS FOR
319,264,425 SHARES OF COMMON STOCK
14,250,000 WARRANTS TO PURCHASE SHARES OF COMMON STOCK
AND
66,845,072 SHARES OF
COMMON STOCK UNDERLYING WARRANTS
OF
EVE HOLDING, INC.
This prospectus
relates to the issuance by us of up to 66,845,072 shares of common stock, comprising (i) the shares of common stock, par value $0.001 per share, that may be issued upon exercise of 11,500,000 outstanding public warrants that were issued to
stockholders in connection with the IPO (the public warrants), originally issued in the IPO as units of Zanite at a price of $10.00 per unit, with each unit consisting of one ordinary share and
one-half of one warrant (see Frequently Used Terms below for certain defined terms used in this prospectus), (ii) the shares of common stock that may be issued upon exercise of
14,250,000 outstanding private placement warrants originally issued at a price of $1.00 per warrant held by certain parties to the Amended and Restated Registration Rights Agreement (the private placement warrants), and (iii) up to
41,095,072 shares of common stock that may be or have been issued upon exercise of new warrants that have been issued or are issuable, subject to triggering events, to United Airlines Ventures, Ltd., a Cayman Islands company (United),
and certain Strategic PIPE Investors (the new warrants). Each public warrant and private placement warrant entitles the holder thereof to purchase one share of common stock at a price of $11.50 per share. For the new warrants, 24,095,072
shares of common stock can be or have been purchased at a price of $0.01 per share contingent on the achievement of certain UAM Business milestones described herein, 12,000,000 shares of common stock can be purchased at $15.00 per share without
further contingency, and 5,000,000 shares of common stock can be purchased at $11.50 per share without further contingency. Of the 24,095,072 shares of common stock subject to new warrants with an exercise price of $0.01 per share, 800,000 shares of
common stock were purchased for $8,000 at the Closing, 2,722,536 shares of common stock were purchased for $27,225.36 on October 14, 2022, and the remaining shares of common stock may be issued under such warrants upon the achievement of
certain UAM Business milestones following the Closing, as applicable for each Strategic Investor. Assuming the exercise of all warrants, we would receive the proceeds from such exercise in cash, which amount of aggregate proceeds could be up to
approximately $533,865,951. We believe the likelihood that warrant holders will exercise their warrants, and therefore the amount of cash proceeds that we would receive is, among other things, dependent upon the market price of our common stock and
whether certain milestones are achieved. There can be no assurance that the UAM Business milestones will be achieved. In addition, even if they are achieved, if the market price for shares of our common stock is less than the exercise price of
a holders warrants, such holder may be less likely to exercise the warrants as such holder would be selling at a loss if they sold their common stock. In addition, such warrants and the shares issuable upon exercise of such warrants are, in
certain cases, subject to lock-up restrictions described herein.
This prospectus also relates to
the resale by certain of the Selling Securityholders named in this prospectus of up to 319,264,425 shares of common stock, comprising (i) 220,000,000 shares of common stock issued in connection with the business combination with Embraers urban
air mobility business, originally issued at a price of $10.00 per share in exchange for Embraers interests in EVE UAM, LLC, (ii) 35,730,000 shares of common stock issued to certain qualified institutional buyers and accredited investors in
private placements consummated in connection with the business combination, originally issued at a price of $10.00 per share, (iii) 5,750,000 shares of common stock that were converted in connection with the business combination on a one-to-one basis from Zanite Class B common stock originally issued at a price of $0.004 per share, (iv) 260,000 shares of common stock underlying restricted stock units
granted to certain directors and an officer of Eve Holding, (v) 140,000 restricted shares of common stock granted to an officer of Eve Holding, (vi) up to 14,250,000 shares of common stock that may be issued upon exercise of private placement
warrants held by certain parties to the Amended and Restated Registration Rights Agreement, originally issued at a price of $1.00 per warrant, (vii) up to 41,095,072 shares of common stock that may be or have been issued upon exercise of new
warrants that have been issued or are issuable, subject to triggering events, to United and certain Strategic PIPE Investors originally issued in connection with entering into certain commercial arrangements without the payment of any purchase price
and (viii) 2,039,353 shares of common stock issued to United in a private placement consummated on September 6, 2022 for a purchase price per share of $7.36 and an aggregate purchase price of $15,000,000.
This prospectus also relates to the resale by certain of the Selling Securityholders of 14,250,000 private placement warrants held by certain
parties to the Amended and Restated Registration Rights Agreement, originally issued at a price of $1.00 per warrant.
We are registering
the securities for resale pursuant to the Selling Securityholders registration rights under certain agreements between us and the Selling Securityholders. Our registration of the securities covered by this prospectus does not mean that the
Selling Securityholders will offer or sell any of the shares of common stock or warrants. Subject to the terms of the Amended and Restated Registration Rights Agreement, as applicable, certain of the Selling Securityholders may offer, sell or
distribute all or a portion of their shares of common stock, public warrants or private placement warrants publicly or through private transactions at prevailing market prices or at negotiated prices. We provide more information about how the
Selling Securityholders may sell the shares of common stock or warrants in the section entitled Plan of Distribution.
We
will receive the proceeds from any exercise of the warrants for cash, but not from the resale of the shares of common stock or warrants by the Selling Securityholders.
We will bear all costs, expenses and fees in connection with the registration of the shares of common stock and warrants. The Selling
Securityholders will bear all commissions and discounts, if any, attributable to their respective sales of the shares of common stock and warrants.
As of the open of trading on May 10, 2022, our common stock and public warrants, began trading on the New York Stock Exchange under the
symbols EVEX and EVEXW, respectively. On April 24, 2023, the last quoted sale price for our common stock as reported on NYSE was $7.53 per share and the last quoted sale price for our public warrants was $0.34 per
warrant.
The common stock and the common stock issuable upon exercise of the resale securities noted above represent a substantial
percentage of the total outstanding shares of common stock as of the date of this prospectus. Additionally, if all of the warrants are exercised, including the new warrant exercised for 800,000 shares of common stock at Closing, the new warrants
exercised for 2,722,536 shares of common stock on October 14, 2022, the Selling Securityholders would own 55,345,072 shares of common stock, representing 17.25% of the total outstanding common stock. The securities beneficially owned by Embraer
Aircraft Holding, Inc. being offered in this prospectus represent over 88% of the total outstanding shares of common stock. So long as the registration statement of which this prospectus is a part is effective, the sales of the securities being
offered in this prospectus could result in a significant decline in the public trading price of common stock. The sales of certain such securities are subject to lock-up restrictions and the shares issuable
upon exercise of certain of the new warrants are subject to the achievement of certain milestones. Furthermore, if the market price for shares of common stock is less than the exercise price of a holders warrant, such holder may be less likely
to exercise the warrants as such holder would be selling at a loss if they sold their common stock. If the market price for shares of common stock is less than $10.00 per share, holders of shares of common stock would be selling at a loss if they
purchased the shares of common stock at $10.00 per share. Because certain selling securityholders purchased shares privately at a price below the current market price, they may have an incentive to sell shares of their common stock because they
could profit despite the market price of common stock falling below $10.00 per share. For example, while United, certain of the Strategic Investors and parties to the Amended and Restated Registration Rights Agreement are currently subject to lock
up restrictions as described herein, based on the closing price of common stock of $7.53 as of April 24, 2023, such stockholders could, on average, make a potential profit of up to approximately $1.12 per share, or up to approximately
$58.2 million in the aggregate (after giving effect to the issuance of common stock issuable upon exercise of warrants), and the Sponsor could make a potential profit of up to approximately $4,50 per share, or up to approximately
$37.1 million in the aggregate. While these selling securityholders may, on average, experience a positive rate of return based on the current market price, public securityholders may not experience a similar rate of return on the securities
they purchased due to differences in the purchase prices and the current market price.
We are an emerging growth company, as
defined under the federal securities laws, and, as such, may elect to comply with certain reduced public company reporting requirements for this prospectus and for future filings.
Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the
risks of investing in our securities in Risk Factors beginning on page 12 of this prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
Prospectus
dated April 26, 2023